Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review

References

• Arciniegas DB. Psychosis. Continuum. 2015;21:715–736. doi: 10.1212/01.CON.0000466662.89908.e7
   PubMedGoogle Scholar
• Fleischhacker WW, Arango C, Arteel P, et al. Schizophrenia–time to commit to policy change. Schizophr Bull. 2014;40(Suppl 3):S165–S194. doi: 10.1093/schbul/sbu006
   PubMed Web of Science ®Google Scholar
• Patel KR, Cherian J, Gohil K, et al. Schizophrenia: overview and treatment options. P T. 2014;39(9):638–645.
   PubMedGoogle Scholar
• Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141. doi: 10.1371/journal.pmed.0020141
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—an overview. JAMA Psychiatry. 2020;77(2):201–210. doi: 10.1001/jamapsychiatry.2019.3360
   PubMed Web of Science ®Google Scholar
• McCutcheon RA, Pillinger T, Mizuno Y, et al. The efficacy and heterogeneity of antipsychotic response in schizophrenia: a meta-analysis. Mol Psychiatry. 2021;26(4):1310–1320. doi: 10.1038/s41380-019-0502-5
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79–104. doi: 10.1038/sj.mp.4001556
   PubMed Web of Science ®Google Scholar
• Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1081–1090. doi: 10.1016/j.pnpbp.2003.09.004
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939–951. doi: 10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Jerrell JM. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Archives Of Pediatrics & Adolescent Medicine. 2008;162(10):929–935. doi: 10.1001/archpedi.162.10.929
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Kwan ATH, Rosenblat JD, et al. Psychotropic drug–related weight gain and its treatment. Am J Psychiatry. 2024;181(1):26–38. doi: 10.1176/appi.ajp.20230922
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777. doi: 10.2147/TCRM.S117321
   PubMed Web of Science ®Google Scholar
• Dencker D, Wörtwein G, Weikop P, et al. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline. J Neurosci. 2011;31(16):5905–5908. doi: 10.1523/JNEUROSCI.0370-11.2011
   PubMed Web of Science ®Google Scholar
• Mirza NR, Peters D, Sparks RG. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev. 2003;9(2):159–186.
   PubMedGoogle Scholar
• Raedler TJ, Bymaster FP, Tandon R, et al. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry. 2007;12(3):232–246. doi: 10.1038/sj.mp.4001924
   PubMed Web of Science ®Google Scholar
• Shekhar A, Potter WZ, Lightfoot J, et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008;165(8):1033–1039. doi: 10.1176/appi.ajp.2008.06091591
   PubMed Web of Science ®Google Scholar
• Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717–726. doi: 10.1056/NEJMoa2017015
   PubMed Web of Science ®Google Scholar
• Shannon HE, Bymaster FP, Calligaro DO, et al. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther. 1994;269(1):271–281.
   PubMed Web of Science ®Google Scholar
• Stanhope KJ, Mirza NR, Bickerdike MJ, et al. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther. 2001;299(2):782–792.
   PubMed Web of Science ®Google Scholar
• Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54(4):465–473. doi: 10.1001/archneur.1997.00550160091022
   PubMed Web of Science ®Google Scholar
• Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet. 2005;44(7):701–720. doi: 10.2165/00003088-200544070-00003
   PubMed Web of Science ®Google Scholar
• Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171(6 Part 1):2311–2315. doi: 10.1097/01.ju.0000127742.73136.0c
   PubMed Web of Science ®Google Scholar
• Sparacino G, Verdolini N, Vieta E, et al. Existing and emerging pharmacological approaches to the treatment of mania: a critical overview. Transl Psychiatry. 2022;12(1):169. doi: 10.1038/s41398-022-01928-8
   PubMed Web of Science ®Google Scholar
• van der Westhuizen ET, Choy KHC, Valant C, et al. Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias. Front Pharmacol. 2020;11:606656. doi: 10.3389/fphar.2020.606656
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Breier A, Kavanagh S, et al. Antipsychotic efficacy of KarXT (Xanomeline−trospium) [Internet]. J Clin Psychiatry. 2022;83(3). doi: 10.4088/JCP.21m14316
   PubMedGoogle Scholar
• Better systematic review management [internet]. Covidence. 2020 [cited 2023 Aug 4]. Available from: http://covidence.org
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, W64. doi: 10.7326/0003-4819-151-4-200908180-00135
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Savović J, Page MJ, et al. Assessing risk of bias in a randomized trial [internet]. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019. 205–228. https://onlinelibrary.wiley.com/doi/10.1002/9781119536604.ch8
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. Declaración PRISMA 2020: una guía actualizada para la publicación de revisiones sistemáticas. Rev Esp Cardiol. 2021;74(9):790–799. doi: 10.1016/j.recesp.2021.06.016
   PubMed Web of Science ®Google Scholar
• Barak S, Weiner I The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia [internet]. Int J Neuropsychopharmacol. 2011;(9): 1233–1246. Available from. doi: 10.1017/s1461145710001549
   PubMed Web of Science ®Google Scholar
• Andersen MB, Fink-Jensen A, Peacock L, et al. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 2003;28(6):1168–1175. doi: 10.1038/sj.npp.1300151
   PubMed Web of Science ®Google Scholar
• Jones CK, Eberle EL, Shaw DB, et al. Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. J Pharmacol Exp Ther. 2005;312(3):1055–1063. doi: 10.1124/jpet.104.075887
   PubMed Web of Science ®Google Scholar
• Swerdlow NR. Prepulse inhibition of startle in humans and laboratory models. Encyclopedia of Neuroscience. Academic Press; 2009.
   Google Scholar
• Feifel D, Shilling PD. Chapter 30 - Modeling Schizophrenia in Animals. In: Conn P, editor. Animal models for the study of human disease. Boston: Academic Press; 2013. p. 727–755.
   Google Scholar
• Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet. 2024;403(10422):160–170. doi: 10.1016/S0140-6736(23)02190-6
   PubMed Web of Science ®Google Scholar
• McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12(1):55–61. doi: 10.1002/jrsm.1411
   PubMed Web of Science ®Google Scholar
• Wilson GH, Baheza R, Barry RL, et al. Pharmacological MRI reveals xanomeline modulation of amphetamine-induced brain activation. Biological psychiatry. NEW YORK (NY) 10169 USA: ELSEVIER SCIENCE INC STE 800, 230 PARK AVE; 2016;266S–266S.
   Google Scholar
• Kaul I, Citrome L, Sawchak S, et al. Poster 32.
   Google Scholar
• Paul SM, Yohn SE, Popiolek M, et al. Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia. Am J Psychiatry. 2022;179(9):611–627. doi: 10.1176/appi.ajp.21101083
   PubMed Web of Science ®Google Scholar
• Kavoussi R, Miller AC, Brannan SK, et al. Xanomeline plus trospium: a novel strategy to enhance pro-muscarinic efficacy and mitigate peripheral side effects. American Society of Clinical Psychopharmacology; 2017.
   Google Scholar
• Sauder C, Allen L, Baker E, et al. KarXT treatment improves cognitive performance in cognitively impaired patients with schizophrenia: a post hoc analysis of the phase 2 EMERGENT-1 study [Internet]. [cited 2023 May 30]. Available from: https://karunatx.com/wp-content/uploads/2022/08/ECNP-2021-P.0794-A4-2021-09-03.pdf
   Google Scholar
• Hulme EC, Birdsall NJ, Buckley NJ. Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol. 1990;30(1):633–673. doi: 10.1146/annurev.pa.30.040190.003221
   PubMedGoogle Scholar
• Aubert I, Ghorayeb I, Normand E, et al. Phenotypical characterization of the neurons expressing the D1 and D2 dopamine receptors in the monkey striatum. J Comp Neurol. 2000;418(1):22–32. doi: 10.1002/(SICI)1096-9861(20000228)418:1<22:AID-CNE2>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Flynn DD, Ferrari-DiLeo G, Mash DC, et al. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer’s disease. J Neurochem. 1995;64(4):1888–1891. doi: 10.1046/j.1471-4159.1995.64041888.x
   PubMed Web of Science ®Google Scholar
• Deutch AY. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl. 1992;36:61–89.
   PubMedGoogle Scholar
• Shannon HE, Hart JC, Bymaster FP, et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther. 1999;290(2):901–907.
   PubMed Web of Science ®Google Scholar
• Montani C, Canella C, Schwarz AJ, et al. The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain. Neuropsychopharmacol. 2021;46(6):1194–1206. doi: 10.1038/s41386-020-00916-0
   PubMed Web of Science ®Google Scholar
• Gozzi A, Jain A, Giovannelli A, et al. A neural switch for active and passive fear. Neuron. 2010;67(4):656–666. doi: 10.1016/j.neuron.2010.07.008
   PubMed Web of Science ®Google Scholar
• Bender AM, Jones CK, Lindsley CW. Classics in Chemical Neuroscience: xanomeline. ACS Chem Neurosci. 2017;8(3):435–443. doi: 10.1021/acschemneuro.7b00001
   PubMed Web of Science ®Google Scholar
• Coyle JT. NMDA receptor and schizophrenia: a brief history. Schizophr Bull. 2012;38(5):920–926. doi: 10.1093/schbul/sbs076
   PubMed Web of Science ®Google Scholar
• Marino MJ, Rouse ST, Levey AI, et al. Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci USA. 1998;95(19):11465–11470. doi: 10.1073/pnas.95.19.11465
   PubMed Web of Science ®Google Scholar
• Correll CU, Angelov AS, Miller AC, et al. Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia. Schizophrenia (Heidelb). 2022;8(1):109. doi: 10.1038/s41537-022-00320-1
   PubMedGoogle Scholar